Milena Pavlova, MD, neurologist and medical director of the sleep testing center at Brigham and Women’s Faulkner Hospital, discusses the profound effect obstructive sleep apnea has on epilepsy as well as cognition.
Obstructive sleep apnea (OSA) worsens both epilepsy and cognitive function, says Milena Pavlova, MD, neurologist and medical director of the sleep testing center at Brigham and Women’s Faulkner Hospital.
Transcript
What is the relationship between obstructive sleep apnea and epilepsy?
I would say it's bidirectional, but mostly in the direction of sleep apnea worsening epilepsy. It’s very straightforward in several ways: one is the hypoxemia and the fact that it overall worsens health, and then the other aspect is the frequent arousals because the patient needs to wake up to breathe. That is worsening the control of seizures as we discussed in the previous talk, it probably also leads to a lot of more complex changes within the human body that basically can favor both worse health, higher risk of cardiovascular, cerebrovascular disease, and various other things. Even more inflammatory changes that can have a further effect. Very simply, frequent arousals can increase the frequency of seizures. In the hospital when we try to record seizures for the purposes of surgical planning for example, we sleep deprive patients in order to facilitate recording of seizures. So, it is something that's has a fairly powerful effect. Sleep apnea worsens epilepsy, and worsens cognitive function actually, that's one of the slides. A few years ago, we looked at, specifically patients with untreated sleep apnea before the treatment of sleep apnea, who were diagnosed with sleep apnea and had epilepsy. They had a very strong correlation between the time spent under normal oxygen level. So, oxygen saturation level below 90% correlated with worse functioning, worse performance on the tests. So, the severity of sleep apnea also correlates with the cognitive functioning of epilepsy patients.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More